Vertex Hopes to Channel CF Drug Successes into Other Therapies in the Pipeline

Vertex Hopes to Channel CF Drug Successes into Other Therapies in the Pipeline

Source: 
BioSpace
snippet: 

Boston, Mass.-based Vertex Pharmaceuticals said in a second-quarter earnings call on Thursday that its revenue has increased 18% compared with Q2 2020, a rise solely driven by the company's six cystic fibrosis (CF) drugs.